Renal Biomarkers: Technologies and Global Markets
The in vitro diagnostic renal biomarker market was valued at $771 million in 2013 and $812 million in 2014. The market is expected to reach $1.1 billion by 2019, a compound annual growth rate (CAGR) of 7% from 2014 to 2019.
- A comprehensive analysis of renal biomarkers global markets and technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Details pertaining to the history and current state of chronic kidney disease (CKD), background information on renal biomarkers, and current industrial technologies used for diagnosis.
- In-depth analyses of the predominant biomarkers in the market, namely creatinine, and emerging biomarkers like NGAL, KIM-1, L-FABP and many others.
- Discussion concerning intellectual property, the regulatory requirement, and the competitive landscape of the industry.
- Comprehensive profiles of major players in the renal biomarkers field.
The report presents current and projected assay forecasts during the forecast period (2014 to 2019). In addition, the study also includes emerging assays with regulatory approval and others expected to achieve Food and Drug Administration (FDA) approved by 2015 within the forecast period. Estimates are used for 2014, except in cases where actual results have been reported. For large market segments such as creatinine and cystatin C, the report discusses their analytical sensitivities and cutoff references in detail, as well as the glomerular filtration rate estimation for diagnosis and prognosis values. The study also focuses on ongoing efforts in developing biomarkers for acute kidney injury.
The report includes analysis of leading and emerging competitors in the current worldwide diagnostic market for kidney diseases. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed, along with their specific product strategies. Detailed profiles of current market leaders are included, as well as profiles of companies with innovative products poised to advance within the forecast period. Market figures are based on revenues at the manufacturers’ level and are projected at 2014-dollar value. Inflation is not computed into projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence of diagnosis for respective diseases. In addition, the report includes forecasts by product, product category and company from 2013 through 2019. The study is arranged to offer an overview of the diagnostic market accompanied by product, company and region.
Excluded from this report are non-proteomic diagnoses (i.e., molecular diagnostics), imagining technology or pharmaceutical biomarkers. Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of sales change. Sales figures do not account for variation in local currencies. All market share data presented is on a global basis, unless specifically noted.
Cheng-Yuk Lee is a life sciences researcher and engineer. He has experience in preclinical and translational medicine research in a pharmaceutical company and led several assay developments as a scientist in a private in vitro diagnostic company with campuses in China and the U.S. He received a dual Bachelor of Science degree in chemical engineering and biochemistry and subsequently completed his Ph.D. in chemical engineering and post-doctoral training. Prior to his professional career, he provided marketing research and strategic business planning for the Office of Corporate Relations at a public research university.